Abstract 829
Background
there is little solid evidence of the effectiveness of psychological interventions using MBRS program for those with advanced cancer. The objective of this study was to evaluate the acceptability and potential benefits of MBSR for pt with cancer pain in early palliative care.
Methods
Main inclusion criteria were: advanced cancer pt in early palliative care; NRS >3;PS >60% according to Karnosky, informed consent. 20 advanced cancer pt were enrolled. Each session included different forms of mindfulness meditation practice, mindful awareness during yoga postures and mindfulness during stressful situations. Participants enter upon enrolling into a commitment to carry out daily 45-min homework assignments .A dedicate nurse with experience in palliative care attended each mindfulness session. Primary outcome was total pain at the end of MBSR intervention evaluated by both VAS and ESAS scales. Secondary outcome was mood state change evaluated by POMS questionnaire. Satisfaction of treatment and compliance were also evaluated. All questionnaires along with a form for collecting personal and clinical data were administered by nurse at baseline and at the end of MBSR intervention.
Results
19 out of 20 were female with median age 54 years old. 56% were receiving morphine for cancer pain. Preliminary results did show slight reduction in total pain score which however was not statistically significant. The POMS test showed significant changes in the mean scores indicating a statistically significant improvement of mood at the end of mindfulness sessions. Compliance program and homework was 70% while pt satisfaction was 78%.
Conclusions
This program appears to be feasible and well accepted. The improvements in the mood state suggests that the mindfulness techniques could play a role in helping patients to reduce mood disturbance. The role of nurse was optimal to allow critically ill patients to participate in MBRS and to guarantee adherence and satisfaction. Moreover nurse was very helful to support the mindfulness trainer in managing cancer patients according to their physical needs. Finally the presence of nurse has been evaluated by patients as part of cancer caring.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Fabrizio Artioli.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2600 - Atezolizumab (atezo) vs chemotherapy (chemo) in patients (pts) with platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): a long-term overall survival (OS) and safety update from the Phase III IMvigor211 study
Presenter: Michiel Van der Heijden
Session: Poster Display session 3
Resources:
Abstract
3598 - Three-Year Follow-Up From the Phase 3 KEYNOTE-045 Trial: Pembrolizumab (Pembro) Versus Investigator’s Choice (Paclitaxel, Docetaxel, or Vinflunine) in Recurrent, Advanced Urothelial Cancer (UC)
Presenter: Andrea Necchi
Session: Poster Display session 3
Resources:
Abstract
2382 - First Report of Efficacy and Safety From a Phase 2 Trial of Tislelizumab, an Anti-PD-1 Antibody, for the Treatment of PD-L1+ Locally Advanced or Metastatic Urothelial Carcinoma (UC) in Asian Patients
Presenter: Dingwei Ye
Session: Poster Display session 3
Resources:
Abstract
2388 - Quality of Life of Metastatic Urothelial Cancer (mUC) Patients Treated with Enfortumab Vedotin (EV) Following Platinum-Containing Chemotherapy and a Checkpoint Inhibitor (CPI): Data from EV-201 Cohort 1
Presenter: Bradley McGregor
Session: Poster Display session 3
Resources:
Abstract
3748 - Safety and efficacy of atezolizumab (atezo) in patients (pts) with autoimmune disease (AID): subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma
Presenter: Yohann Loriot
Session: Poster Display session 3
Resources:
Abstract
1126 - Validation of the VIO prognostic index in patients with metastatic urothelial carcinoma treated with immune-checkpoint inhibitors
Presenter: Rafael Morales Barrera
Session: Poster Display session 3
Resources:
Abstract
3693 - Pathologic outcomes after neoadjuvant chemotherapy for high-risk muscle invasive bladder cancer
Presenter: Justin Matulay
Session: Poster Display session 3
Resources:
Abstract
4840 - Analysis of response to prior therapies and therapies after treatment with erdafitinib in fibroblast growth factor receptor (FGFR)-positive patients (pts) with metastatic urothelial carcinoma (mUC)
Presenter: Arlene Siefker-Radtke
Session: Poster Display session 3
Resources:
Abstract
1221 - Clinical outcomes by sex with atezolizumab (atezo) monotherapy in patients (pts) with locally advanced/metastatic urothelial carcinoma (mUC)
Presenter: Jean Hoffman-censits
Session: Poster Display session 3
Resources:
Abstract
1715 - National Small Cell Bladder Cancer Audit: Results from 26 UK institutions
Presenter: Caroline Chau
Session: Poster Display session 3
Resources:
Abstract